Clinicopathological and Prognostic Significance of Long Non-coding RNA MIAT in Human Cancers: A Review and Meta-Analysis

Yongfeng Wang; Liangyin Fu; Tingting Lu; Guangming Zhang; Jiawei Zhang; Yuanbin Zhao; Haojie Jin; Kehu Yang; Hui Cai

doi:10.3389/fgene.2021.729768

Clinicopathological and Prognostic Significance of Long Non-coding RNA MIAT in Human Cancers: A Review and Meta-Analysis

Front Genet. 2021 Sep 30:12:729768. doi: 10.3389/fgene.2021.729768. eCollection 2021.

Authors

Yongfeng Wang^{1

2

3

4}, Liangyin Fu^{1

2

3}, Tingting Lu⁵, Guangming Zhang^{1

2

3}, Jiawei Zhang⁶, Yuanbin Zhao⁶, Haojie Jin⁷, Kehu Yang^{4

5

8}, Hui Cai^{1

2

3}

Affiliations

¹ The First Clinical Medical College of Gansu University of Chinese Medicine (Gansu Provincial Hospital), Lanzhou, China.
² General Surgery Clinical Medical Center, Gansu Provincial Hospital, Lanzhou, China.
³ Key Laboratory of Molecular Diagnostics and Precision Medicine for Surgical Oncology in Gansu Province, Gansu Provincial Hospital, Lanzhou, China.
⁴ Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China.
⁵ Institution of Clinical Research and Evidence Based Medicine, Gansu Provincial Hospital, Lanzhou, China.
⁶ Second Clinical Medical College, Lanzhou University, Lanzhou, China.
⁷ The First Clinical Medical College of Lanzhou University, Lanzhou, China.
⁸ Key Laboratory of Evidence Based Medicine and Knowledge Translation of Gansu Province, Lanzhou, China.

Abstract

Background: Although the treatment of cancer has made evident progress, its morbidity and mortality are still high. A tumor marker is a critical indicator for early cancer diagnosis, and timely cancer detection can efficiently help improve the prognosis of patients. Therefore, it is necessary to identify novel markers associated with cancer. LncRNA myocardial infarction associated transcript (MIAT) is a newly identified tumor marker, and in this study, we aimed to explore the relationship between MIAT and clinicopathological features and patient prognosis. Methods: We searched PubMed, Embase, Web of Science, and The Cochrane Library from inception to September 2020 to identify correlational studies. Then, we extracted valid data and used Stata software to make forest plots. We used the hazard ratio (HR) or odds ratio (OR) with 95% CI to evaluate the relationship between aberrant expression of MIAT and patients' prognosis and clinicopathological features. Results: The study included 21 studies, containing 2,048 patients. Meta-analysis showed that overexpression of lncRNA MIAT was associated with poor overall survival (OS) (HR = 1.60, 95% CI, 1.31-1.96, p < 0.001). In addition, high expression of MIAT could forecast tumor size (OR = 2.26, 95% CI 1.34-3.81, p = 0.002), distant metastasis (OR = 2.54, 95% CI 1.84-3.50, p < 0.001), TNM stage (OR = 2.38, 95% CI 1.36-4.18, p = 0.002), lymph node metastasis (OR = 2.59, 95% CI 1.25-5.36, p = 0.011), and the degree of differentiation (OR = 2.65, 95% CI 1.54-4.58, p < 0.001). However, other clinicopathological features, including age (OR = 1.07, 95% CI 0.87-1.32, p = 0.516), gender (OR = 0.95, 95% CI 0.77-1.19, p = 0.668), and histology (OR = 0.72, 95% CI 0.48-1.10, p = 0.128) were not significantly different from high expression of MIAT. Conclusions: Our study showed that overexpression of MIAT is related to poor overall survival and clinicopathological features. MIAT can be considered a novel tumor marker to help diagnose tumors earlier and improve patient prognosis.

Keywords: MIAT; cancer; lncRNA; meta-analysis; prognosis.

Publication types

Systematic Review